Multiple myeloma (MM) is a plasma cell malignancy where MM cell growth is supported by the bone marrow (BM) microenvironment with poorly defined cellular and molecular mechanisms. MM cells express CD40, a receptor known to activate autocrine secretion of cytokines and elicit proliferation. Activated T helper (Th) cells express CD40 ligand (CD40L) and BM Th cells are significantly increased in MM patients. We hypothesized that activated BM Th cells could support MM cell growth. We here found that activated autologous BM Th cells supported MM cell growth in a contact-and CD40L-dependent manner in vitro. 
INTRODUCTION
Patients with multiple myeloma (MM) and monoclonal gammopathy of undetermined significance have significantly increased numbers of T cells in the bone marrow (BM), 1 a microenvironment that also includes cell types such as endothelial cells, fibroblasts, osteoclasts, myeloid-derived suppressor cells (MDSC), macrophages and dendritic cells. 2 This complex niche is still poorly understood and the mechanisms that induce MM cell proliferation remain unclear.
Conceptually, cellular elements may either be detrimental, beneficial or indifferent for MM cell proliferation. T cells can counteract the development of cancer in the act of immunosurveillance. However, cancer cells may edit the immune response 3 and tumors can subvert immunity. 4 Experiments in mice have demonstrated that T cells can kill murine myeloma cell lines. 5 Nevertheless, MM cells may eventually escape T cytotoxicity. 6, 7 Recently, a new mechanism of escape was demonstrated with human primary MM cells: MM cells deactivated the proteasomal pathway in dendritic cells via binding of CD28 (MM cells) to CD80/86 (dendritic cells), and protected themselves from CD8 + T cell killing. 8 Concerning T helper (Th) cells, tumor cells including MM cells may evade cytotoxic immune responses by facilitating a skewed immune response, promoting a protective cytokine environment and by favoring noncytotoxic Th cell subtypes as well as other immune cells. 6, 9, 10 On the other hand, Th cells also had an active role in both lymphomagenesis in mice 11 and supported malignant B cells in humans. [12] [13] [14] In fact, others have speculated that myeloma-specific Th cells can accommodate MM cells by secreting MM-supportive cytokines. 15 Similarly, Th17 cell cytokines promoted the growth of MM cell lines in vitro and in vivo and supported colony formation of primary human MM cells. 16 The BM is an important niche for memory Th cells both in healthy individuals and MM patients 1, 2, 17, 18 and activated Th cells with high surface CD40L expression have been found in the human BM. 2, [17] [18] [19] [20] [21] [22] Interestingly, MM cells express high levels of CD40; CD40 signaling triggers the NF-κB pathway and secretion of several pro-survival factors. [23] [24] [25] It is therefore plausible that CD40 activation could have a role for primary MM cell proliferation, but it has yet to be resolved whether these activated Th cells can in fact support MM cell proliferation in vitro and in vivo.
To investigate the potential effect of activated Th cells on primary MM cells, we polyclonally stimulated BM Th cells and analyzed the net effect of the Th subsets present. Activated autologous Th cells were tested for their ability to support MM cells in vitro and in vivo. We also performed assays where primary MM cells were tested for their ability to activate and collaborate with allogeneic Th cells. The latter experiments were feasible because primary human MM cells are antigen presenting cells and can present antigen to Th cells.
at Oslo University Hospital and Drammen Hospital. BM and blood samples from MM patients were collected from patients that were untreated (32 patients) or had relapsed after one or more treatments (22 patients), see Supplementary Information for details. Blood and BM samples from five healthy individuals were used in the experiments as indicated. Functional studies were performed on IgG + or IgA + patients as indicated in the figure legends.
Cell purification, culture and microscopy MM cells were purified from BM aspirates of MM patients using MACS CD138 + microbeads (Miltenyi, Bergisch Gladbach, Germany). Purified MM cells were 498% CD138 + and 495% of cells expressed the clonal light (L) chain (κ or λ); non-clonal L chain (λ or κ, respectively) were not detected on the MM cells. Further purity analyses were also performed by staining for CD56 and/or CD28, differentiating MM cells from normal plasma cells. 28 As appropriate, these stains were included in the gating strategy for subsequent assays as indicated in figure legends. FlowComp Human CD4 kit (Life Technologies, Carlsbad, CA, USA) was used to purify CD4 + Th cells (497%) from the BM and blood of healthy individuals as well as MM patients. Th cell lines from healthy individuals as well as patients were generated by expanding Th cells using Human T-Activator CD3/CD28 Dynabeads (Life Technologies, abbreviated as anti-CD3/28 beads herein) with 20 U/ml interleukin-2 (IL-2, Roche, Applied Science, Penzberg, Germany) for short-term stimulation lasting 5-7 days. Bright field images were taken with a Nikon Eclipse Ti fluorescent microscope equipped with a high-sensitivity CCD camera (Cascade 512, Photometrics, Tucson, AZ, USA) and a × 40 objective lens. Culture of bulk BM cultures was performed as described in the Supplementary Information by depleting T cell subsets (Dynabeads) and culturing cells in autologous serum and IL-2.
Cell proliferation assays MM cells (0.5-1 × 10 6 ) were co-cultured with rested allogeneic Th cells in a 1:1 ratio. Alternatively, MM cells were co-cultured with either the allogeneic Th cells or autologous BM Th cells directly in the presence of anti-CD3/28 beads. In other settings, MM cells were stimulated with plate coated agonistic anti-human CD40 (1 μg/ml, clone #5C3, BD Biosciences, San Jose, CA, USA) or were co-cultured with 100 Gy irradiated murine L cell fibroblasts expressing human CD40L (herein abbreviated CD40L + L cells).
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Cells were cultured in 6.5 mm well Transwell culture plates (inserts with 0.4 μm pores; Corning, New York, NY, USA). MM cells (5 × 10 5 ) were added to inserts and separated from Th cells, MM cells and anti-CD3/28 beads in the lower wells. Cells were co-cultured for 5 days and tested for DNA replication by BrdU incorporation, BrdU (BrdU stain kit, BD) was added to cell cultures in the final 48 h of assays; cells were stained with anti-BrdU as per manufacturer's protocol. MM cells were stimulated by BM Th cells in the presence of 20 U/ml IL-2 and 10 ng/ml IL-15 (PeproTech, Rocky Hill, NJ, USA) and then were imaged with the Incucyte Zoom microscope with standardized manufacturer's protocol as detailed in the Supplementary Information. Inhibition of MM cell proliferation was performed in the coculture system with Th cells in the presence of 20 μg/ml anti-CD40L (clone #24-31, eBioscience, Waltham, MA, USA) from day 3-5 or with matched isotype (eBioscience).
Th cell migration assay
Purified MM cells were stimulated without/with immobilized anti-CD40 (#5C3, BD). Supernatants (SN) were collected on day 3 for migration assays. The Transwell system (5 μm pore size, Corning) was used to test the migration of freshly purified autologous Th cells (2.5 × 10 5 ) from respective MM patients. Average background migration towards fresh medium was 6%. The enhanced Th cell migration (Δ migration) towards MM supernatant was calculated by subtracting the 6% background.
Flow cytometry
Cells were stained with combinations of the following fluorochrome labeled mAbs: from eBioscience, mAbs were specific for λ L chain (4C2), κ L chain (A8B5), CD4 (OKT4), CD28 (37.51), HLA-DR (LN3), CCR5 (T21/8), CCR6 (R6H1), PD-1 (J105), Bcl-6 (BCL-UP), T-bet (4B10), GATA3 (TWAY), IL-2 (MQ1-17H12), IL-4 (8D4-8), IL-17 (eBio64DEC17), IL-21 (3A3-N2) and TNFα (MAb11). mAbs from Biolegend (San Diego, CA, USA) were specific for: CXCR3 (TG1) and IL-13 (PVM13-1). mAbs from BD Bioscience (San Diego, CA, USA) were specific for: CXCR5 (RF8B2), CD56 (B159), CD138 (MI15), CRTH2 (BM16), RORγt (Q21-559), IFN-γ (25723) and BrdU (552598). Surface staining and intracellular staining were performed as described. 12 Cells were analyzed with FACSCalibur or Fortessa (BD) and FlowJo X software (Tree Star, Ashland, OR, USA). Cells were stained for cytoplasmic Igκ or Igλ L chains as indicated after permbealization with cytoperm/cytofix buffer (BD).
In vivo experiments
Busulfan (Busilvex, Pierre Fabre Pharma, Castres, France) pre-conditioned NOD SCID gamma null mice (NSG, The Jackson Laboratory, Bar Harbor, ME, USA) were used in xenotransplantation with MM and Th cells. 12 Mice were injected i.v. with purified MM cells (8 × 10 6 ) or MM cells and autologous BM Th cells (4 × 10 6 ). Alternatively, whole BM cultures were cultured as described in figure legends and 
ELISA and measurement of cytokines
Serum samples were used to determine IgGκ and IgGλ concentration by ELISA; 12 IgG was captured with anti-human IgG (I2136) and detected with alkaline phosphatase conjugated anti-κ L chain (A3813) or anti-λ L chain (A2904, Sigma-Aldrich, St Louis, MO, USA). Cytokines from SN were collected on day 3 for Bio-Plex cytokine assay (Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions. ELISA kits were used to measure IL-23 (eBioscience) and RANKL (PeproTech).
Statistical analysis
Statistical analysis was calculated using two tailed Student's t-test or two tailed Mann-Whitney Test with GraphPad Prism 5.02 (GraphPad Software, San Diego, CA, USA). A P-valueo0.05 was considered statistically significant. (Figure 2a, right histogram) . In these expanded BM Th cells, we found that the Th MYEL produced lower amounts of cytokines such as IL-4, IL-10, IL-13, GM-CSF, IFN-γ and TNF-α, and more of IL-6, IL-1β, IL-2, IL-17, CCL2 (MCP-1) and CCL4 (MIP-1β) (Figure 2b ). Other cytokines included CCL5 (RANTES), CCL3 (MIP-1α), CXCL10 (IP-10), VEGF and IL-9 (Supplementary Figure S3) . Despite these variations, the allogeneic normal Th cells and the activated autologous Th MYEL cells had a very similar capacity to stimulate MM cells (Figures 1a  and b ). Next, we tested whether Th cytokines were sufficient for MM cell proliferation.
RESULTS

Polyclonally activated allogeneic and autologous
Th cell-dependent stimulation of MM cells was dependent on cell contact and CD40L stimulation Using Transwell assays, we found that the presence of Th cytokines was not sufficient to reconstitute full MM cell proliferation. MM cells that were in contact with activated Th cells responded much stronger (Figure 3a) . Proliferation of MM cells could also be induced by co-culture with murine L cells, L cells expressing human CD40L (CD40L + L cells) or by providing agonistic anti-CD40 mAb. The CD40-related responses were seen without addition of exogenous cytokines (Figure 3b ). We next repeated Th cell-MM cell experiments as shown in Figure 1 , but added antagonistic anti-CD40L from day 3-5: blocking CD40L reduced the ability of activated Th MYEL to support the proliferation of MM cells (Figure 3c ).
CD40 stimulated MM cells secreted Th cell attracting cytokines and chemokines We assayed SN from MM cells stimulated by agonistic anti-CD40, and found that the secretion of some cytokines/chemokines was significantly increased in comparison to resting MM cells (N = 6, Po 0.05; Figure 4a ). This included sRANKL, a TNF ligand family member involved in MM pathogenesis and bone resorption. 32, 33 We also found IL-9 and IL-23, which are not previously associated with MM cells. It was of interest whether the inflammatory mediators in MM cell SN could recruit Th cells. We found that these SN attracted Th cells four times as efficiently as SN from unstimulated MM cells, suggesting that CD40L activation of MM cells could further recruit Th cells to MM niches in the BM, MannWhitney test, P = 0.0003, N = 6 (Figure 4b ).
MM cells activated and collaborated with alloreactive Th cells Others have described that a variable but consistent subset of MM cells express HLA-DR and co-stimulatory molecules and that MM cells retain antigen presentation function. 26, 27 We confirmed the finding of HLA-DR expression on the current MM cells (IgG + and IgA + subsets, Figure 5a ). Similar results were found in light chain 18,34 CD40L is predominantly expressed by activated Th cells; activated Th cells further upregulate CD40L surface expression 10 fold within 2-8 h of stimulation. [19] [20] [21] Reciprocally, MM cells retain the ability to stimulate Th cells since a subset of MM cells express MHC class II and co-stimulatory molecules. 26, 27 MM cells could therefore potentially present mutated self-epitopes to Th cells and elicit support for proliferation. After a week of culture in autologous serum, bulk BM cultures gradually expanded as both Th cells and MM cells were spontaneously activated, and MM cell expansion (in vitro and in vivo) was abrogated by depletion of Th cells. This suggests that the BM compartment contains Th cells specific for MM cell antigens, a suggestion that is compatible with previous findings on oligoclonal expansions of Th with unknown significance in the MM patients. 1, 35 Clonotypic determinants in the V regions of the BCR (Idiotypes) 6, 11 are plausible antigenic drivers for such Th cell partners. In fact, 0.7-10% of BM Th cells were previously found to respond to monoclonal Ig derived from MM cells. Many of these Ig-specific Th cells secreted Th2-type cytokines. Therefore, Ostad et al. 15 speculated that such Th cells could provide support for MM cell growth.
It has previously been demonstrated that human primary MM cells very poorly engraft into NSG mice without provision of other human BM constituents. 36 When MM cells very rarely engrafted in NSG mice, a multi-lineage reconstitution including T cells and human CD13
+ myeloid stromal cells was found. 36 The current results demonstrate that pre-activated autologous Th cells 2, 41 In our assays these results were confirmed. Moreover, chemokine secretion was significantly upregulated after CD40-activation. The greatest change was in CXCL10 (IP-10), a chemokine that can attract CXCR3 + Th cells (Th1 and Th1/17 or Th1*). We found that an increased proportion of the BM Th cells were CXCR3 + in MM patients. In addition, the BM Th cells often expressed CCR6, a receptor usually found on Th17 cells. It is increasingly clear that Th cells can develop into functional variants, as has also been described for CXCR3 + CCR6 + Th1/17 or Th1* cells in humans. 30, 31 Thus, inflammatory stimuli, for example, IL-1β can skew Th cell phenotypes. 30, 31 The release of such mediators in the MM cell microenvironment by MM cells, Th cells and other cells may have caused the unusual chemokine receptor profile that we observed.
MM cells can also migrate in response to chemokines. MM cells express CCR1, CCR2, CCR5 and CXCR3 and migrate towards CCL3 and CCL5. 42, 43 The pro-inflammatory CCL3 and CCL5 can be secreted by activated Th cells as also seen in our data, suggesting active migration of both Th cells and MM cells towards a Th-MM cell interaction.
The current results and previous findings suggest that Th cells may drive MM growth. Previous findings support this conjecture including descriptions of (1) [23] [24] [25] 44, 45 and (6) the responsiveness of MM cells to Th cell-derived cytokines. 15, 16 We suspect that MM cells have shaped and co-evolved with their microenvironment, co-opting favorable supportive Th cell subtypes, escaping cytotoxic T cell responses and sculpting other elements such as MDSC. Hence, a better understanding of the interplay between T cells and myeloma cells may be of special relevance to immunotherapy.
